CSat Investment Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

CSat Investment Advisory’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$70K	Buy	122 +38	+45%	+$22.5K	0.06%	123
2020 Q4	$49K	Sell	84 -193	-70%	-$110K	0.05%	154
2020 Q3	$143K	Sell	277 -7	-2%	-$3.55K	0.01%	343
2020 Q2	$128K	Buy	284 +147	+107%	+$64.9K	0.02%	398
2020 Q1	$48K	Buy	137 +23	+20%	+$8.46K	0.01%	529
2019 Q4	$42K	Sell	114 -397	-78%	-$140K	0.01%	646
2019 Q3	$170K	Buy	511 +89	+21%	+$29K	0.05%	230
2019 Q2	$132K	Buy	+422	New	+$126K	0.05%	249

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CSat Investment Advisory's BIO Position: Q1 2021 in Review

CSat Investment Advisory increased its Bio-Rad Laboratories Class A (BIO) stake by 45% in Q1 2021, buying an estimated $22.5K and bringing the position to 122 shares worth $70K. The position accounts for 0.06% of the portfolio, ranked #123.

CSat Investment Advisory first reported a position in BIO in Q2 2019 and has held it in 8 quarters since. The position peaked at $170K in Q3 2019. 492 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

CSat Investment Advisory held 122 shares of Bio-Rad Laboratories Class A worth $70K as of Q1 2021.
CSat Investment Advisory bought 38 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $22.5K.
Bio-Rad Laboratories Class A made up 0.06% of CSat Investment Advisory's portfolio in Q1 2021, its #123 holding.
CSat Investment Advisory first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and has held it in 8 quarters since.
CSat Investment Advisory's Bio-Rad Laboratories Class A position peaked at $170K in Q3 2019.
492 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on CSat Investment Advisory's 13F filing for Q1 2021, filed 13 May 2021.